Navigation Links
WWMR Announces Pain Clinic Physicians' Most Appreciated Companies: Pfizer, Eli Lilly and Endo Pharmaceuticals
Date:11/20/2008

ling messages are also captured, as the clinicians report on detailing visits for up to five company sales representatives each month.

"There has been a major gap in resources that report to the biotech, pharmaceutical and medical device industries about prescription drug use and pharmaceutical marketing in pain clinics. The Pain Clinic Monitor is designed to fill this gap. The Pain Clinic Monitor presents a fresh, unique focus on point of care pain prescribing, and a significant opportunity to obtain actionable findings for Product Development, as well as Marketing and Physician Education professionals," stated Susan Olsen, President, WWMR. "There are no other comparable audits available to companies focused on the treatment of pain."

Some of the reasons companies subscribe to the Pain Clinic Monitor include:

    1.  Provides insights from a 10,000 pain-patient database;
    2.  Understanding drug use for 27 different pain conditions;
    3.  Monitor uptake of NEW pain drugs;
    4.  Track reasons for pain drug discontinuations;
    5.  Examine in-office (IV, injectable, oral and topical) pain drug
        administrations;
    6.  Know all the pain drugs a given chronic pain patient is taking;
    7.  Analyze pain drug detailing & detailing messages;
    8.  Profile competitive pain drug uses;
    9.  Connect with the most influential clinicians prescribing for chronic
        pain patients;
    10. Ask ad-hoc questions of a representative panel of pain center
        clinicians;
    11. Support their company's product development, marketing, and physician
        education efforts in the pain therapy area; and
    12. Receive the results of the annual "Most Appreciated Pain Drug Company
        Survey.

WWMR, Inc. is a marketing research and strategic consulting and publishing firm with global capabilities, known for conducting focused and solution-oriented research acro
'/>"/>

SOURCE WWMR, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Wound Management Technologies, Inc. Announces a Published Case Study
2. Histogen Announces Start of Hair Regrowth Clinical Evaluation
3. New Generation Biofuels Announces Test Burn Agreement With Progress Energy Florida
4. KGI Announces Second Annual Executive Education Conference for Women in Life Sciences
5. SyntheMed Announces FDA Clearance of SinusShield(TM)
6. Synvista Therapeutics Announces 510(k) Submission for Its HAPTOCHEK(TM) Test Kit
7. American HealthChoice Announces the First Sales of the OmniBody Scan
8. Tengion Announces Second Closing of Series C Financing
9. Penguin Computing Announces Niveus HTX Personal Supercomputer
10. Convey Computer™ Corporation Announces First Customer: University of California, San Diego at SC08 Conference
11. BBM Announces Offer to Acquire YM BioSciences Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology Technology:Myriant Technologies LLC Selected for $50 Million Award for Succinic Acid Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 2Enerkem Awarded $50 Million Funding by U.S. Department of Energy for its Mississippi Biorefinery Project 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer 2